Fig. 7From: Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancerTwo-dimensional (2D) structure related to the interaction between FGFR3 protein and approved drugs. A Pemigatinib. B Infigratinib. C Nintedanib. D Ponatinib, Red dotted lines indicate hydrophobic bonds and hydrogen bonding shown by green dotted linesBack to article page